NCT00081133View on ClinicalTrials.gov

Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

PHASE1/PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

December 31, 2003

Primary Completion Date

February 28, 2005

Study Completion Date

February 28, 2005

Conditions
Leukemia
Interventions
DRUG

arsenic trioxide

DRUG

imatinib mesylate

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00081133 - Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia | Biotech Hunter | Biotech Hunter